Aronora is Revolutionizing Blood Clot Treatment with Groundbreaking Innovations
Aronora co-founder and CEO Dr. Erik Tucker has been elected as Fellow of the National Academy of Inventors (NAI)
Presentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation
Stars among first to get new three-step formula to help make long distance air travel easy and effortless
Three-step solution to help make long-distance air travel easy and effortless
Enzyme that selectively targets blood clots has received FDA Fast Track designation, allowing for expedited clinical development
Global Community of Leading Experts in the Fields of Thrombosis and Hemostasis Meet in France for First Time in 15 Years
Inaugural World Thrombosis Day Steering Committee Member to Represent Africa